About mckinleymedia

This author has not yet filled in any details.
So far mckinleymedia has created 229 blog entries.
28 Aug, 2020

Unlock the power of DNA

Powered by our ACE Technology, our DNA Assays provide more uniform coverage at high depths than standard assays. Specifically, our ACE-enabled assays outperform conventional exome assays by enhances coverage across coding regions and supplementing more complex areas in the genomic architecture such as GC-rich content. The Personalis solution  provides targeted sequencing to augment coverage gaps [...]

28 Aug, 2020

Better NGS data starts with better processes

Our patented ACE™ (Accuracy and Content Enhanced) Technology is the foundation of ImmunoID NeXT and all proprietary Personalis products. ACE improves processes from nucleic acid preparation, to sequencing, to analytics for superior sequencing results. Nucleic Acid Extraction and Sample Preparation Personalis has developed protocols to overcome the challenges of working with difficult samples including FFPE, [...]

26 Aug, 2020

Advancing the accuracy of MHC binding prediction

HLA binding is currently the most well-established criteria for ranking neoantigen candidates. Recent advances in training data generated from mass spectrometry provide a larger dataset of peptide binders and non-binders for individual HLA alleles. This new binding data takes two important additional components into consideration: cleavage and transportation, which are critically important for presentation assessment. [...]

26 Aug, 2020

Neoantigen Discovery

NeoantigenID Technologies for neoantigen discovery are critical for the development of personalized cancer therapies and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID NeXT Platform® enables a comprehensive survey of putative neoantigens by combining highly sensitive exome- [...]

25 Aug, 2020


The use of single-analyte biomarkers (e.g. PD-L1 expression) has yielded modest results in the quest to accurately predict which patients are likely to respond (or not) to immunotherapies and their combinations with other treatment modalities. In the immunotherapy age, it’s clear that more effective patient stratification techniques will require the integration of multiple biomarkers that [...]

25 Aug, 2020


While understanding the reasons why certain patients are resistant to oncology therapies is important, it is even more critical to ensure that they are administered only to patients who are expected to respond. Therefore, the identification and use of molecular markers that are predictive of response is imperative in bringing the curative potential of [...]

2 Aug, 2020

Next Features

Deep Sequencing ~2,000X mean coverage across the entire ~20,000-gene DNA footprint, as well as boosted ~5,000 mean coverage across ~247 cancer-related genes to deliver enhanced sensitivity. Augmented Coverage NeXT Liquid Biopsy utilizes our proprietary ACE Technology to provide augmented coverage of difficult-to-sequence gene regions across the entire ~20,000-gene footprint. Advanced Error Suppression Our robust variant [...]

2 Aug, 2020

NeXT Liquid Biopsy

NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]

17 Apr, 2020

Stephen Moore, JD

Stephen Moore joined Personalis as General Counsel in April 2020, with more than twenty years in-house legal experience at advanced genomics companies. Prior to joining Personalis, he was General Counsel at Pacific Biosciences, a publicly listed company and pioneer in the field of single molecule, long read DNA sequencing, where he worked for over a [...]

13 Mar, 2020

Whole Genome Sequencing

In recent years, the declining cost of NGS has resulted in the increased use of broad genomic characterization approaches, including whole genome sequencing (WGS), for various research applications. This cost reduction has coincided with researchers’ need for more comprehensive molecular information in the disease areas of cardiology, endocrinology, rare disease, autoimmunity, and ever-increasingly, cancer. WGS [...]

Go to Top